Abstract
BackgroundNilotinib (Tasigna) is a tyrosine kinase inhibitor (TKI) used in the treatment of chronic myeloid leukaemia (CML). Non-adherence to TKIs affects treatment efficacy and leads to higher morbidity and, possibly,...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: European Journal of Hospital Pharmacy: Science and Practice
Paper Title
Journal
Date
